|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1991-8-1
|
|
pubmed:abstractText |
An effective second-line treatment for intermediate and high grade non-Hodgkin's lymphoma is greatly needed since 30% of patients do not achieved complete remission (CR) and another 20% to 30% of the CRs will eventually relapse.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
43-6
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:2055560-Adult,
pubmed-meshheading:2055560-Aged,
pubmed-meshheading:2055560-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2055560-Cisplatin,
pubmed-meshheading:2055560-Dexamethasone,
pubmed-meshheading:2055560-Drug Evaluation,
pubmed-meshheading:2055560-Etoposide,
pubmed-meshheading:2055560-Female,
pubmed-meshheading:2055560-Humans,
pubmed-meshheading:2055560-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2055560-Male,
pubmed-meshheading:2055560-Middle Aged,
pubmed-meshheading:2055560-Mitoxantrone,
pubmed-meshheading:2055560-Remission Induction
|
|
pubmed:articleTitle |
Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Divisione di Ematologia, Ospedale Molinette, Torino, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
